Results 51 to 60 of about 1,814 (132)

Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations

American Journal of Ophthalmology Case Reports, 2020
Purpose: To describe a case of unilateral retinal arteriolar occlusion following multiple intravitreal brolucizumab injections for neovascular age-related macular degeneration (nAMD).
Atul Jain, Sophaktra Chea, Wataru Matsumiya, M. Sohail Halim, Çigdem Yaşar, Guoping Kuang, Yasir J. Sepah, Arshad M. Khanani, Diana V. Do, Quan Dong Nguyen   +9 more
doaj   +1 more source

Conbercept Treatment for Heart‐Shaped Vascular Intertwined Nets in Macular Neovascularization: Anti‐VEGF Drug Therapy Strategy Based on Vascular Geometry Diagnosed by OCTA

Clinical Case Reports, Volume 13, Issue 10, October 2025.
A 63‐year‐old male with a history of hypertension and diabetes developed acute vision loss, which was attributed to macular neovascularization secondary to hypertensive retinopathy. Optical coherence tomography angiography revealed unusual heart‐shaped, intertwined vascular nets, informing the choice of Conbercept for intravitreal injection.
Shangkun Ou, Feiping Shi, Minqing Cai, Yiming Wu   +3 more
wiley   +1 more source

The initial results of using brolucizumab (Beovu®), an angiogenesis inhibitor, for choroidal neovascularization in patients with age-related macular degeneration [PDF]

Клиническая офтальмология, 2022
N.S. Zhayvoronok1, O.V. Kolenko1–3, L.P. Danilova1,2, E.L. Sorokin1,3 1Khabarovsk Branch of the S. Fedorov Eye Microsurgery Federal State Institution, Khabarovsk, Russian Federation 2Institute of Advanced Training of Healthcare Specialists ...
N.S. Zhayvoronok, O.V. Kolenko, L.P. Danilova, E.L. Sorokin   +3 more
doaj  

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, Volume 54, Issue 5, Page 724-726, July 2026.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Recent Advancements in the Treatment of Age‐Related Macular Degeneration

Med Research, Volume 1, Issue 2, Page 151-169, September 2025.
ABSTRACT Age‐related macular degeneration (AMD) is a prevalent cause of visual impairment and blindness among the elderly. AMD can be categorized into two subtypes: “wet” and “dry.” Current treatments for wet AMD mainly involve anti‐vascular endothelial growth factor (VEGF) drugs, and there are three U.S.
Shan Liu, Danyang Lv, Junran Sun, Huixun Jia, Fang Zheng, Felipe Pereira, Siddharth Narendran, Zhenyu Dong, Haiyun Liu, Shunxiang Gao, Peirong Huang   +10 more
wiley   +1 more source

Indication‐Specific Dosing and Dose‐Evaluation Strategies in New Indications for Non‐Oncology Monoclonal Antibodies

The Journal of Clinical Pharmacology, Volume 65, Issue 7, Page 895-908, July 2025.
Abstract Compared to traditional small molecule drugs, monoclonal antibodies (mAbs) often display more complex pharmacokinetic (PK) and pharmacodynamic (PD) properties that may be impacted by disease‐specific factors. For mAbs in non‐oncology indications, where the same drug might be used for conditions involving different organ systems and/or having ...
Sherouk M. Tawfik, Fei Tang
wiley   +1 more source

Brolucizumab: Evaluation of Compassionate Use of a Complex Anti-VEGF Therapy

Clinical Ophthalmology, 2021
Julianna E Murray, Aaron S Gold, Azeema Latiff, Timothy G Murray Private Practice, Miami Ocular Oncology & Retina, Miami, FL, USACorrespondence: Timothy G MurrayMiami Ocular Oncology & Retina, 6705 Red Road Suite 412, Miami, FL, 33143, USAEmail tmurray ...
Murray JE, Gold AS, Latiff A, Murray TG
doaj  

Linking preclinical models to clinical realities: VEGF/VEGFR inhibitors and thrombotic microangiopathy in cancer therapy

iMetaOmics, Volume 2, Issue 2, June 2025.
This study investigates the risk of thrombotic microangiopathy (TMA) induced by vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) inhibitors in cancer therapy. Using data from the FDA Adverse Event Reporting System (FAERS), the WHO Global Database for Adverse Drug Reactions (Vigibase), and The Cancer ...
Aimin Jiang, Zhanzhi Li, Ying Liu, Junyi Shen, Quan Cheng, Anqi Lin, Peng Luo, Linhui Wang   +7 more
wiley   +1 more source

High-Dose Brolucizumab for Refractory Neovascular Age-Related Macular Degeneration Resistant to Standard-Dose Brolucizumab

Ophthalmology and Therapy
Introduction The aim of this study was to evaluate the efficacy and safety of escalating the dosage of intravitreal brolucizumab in patients with refractory neovascular age-related macular degeneration (AMD).
Jinsoo Kim, Min Seon Park, Bum-Joo Cho, Soonil Kwon   +3 more
doaj   +1 more source

Two-Years Real-World Experience of a Tertiary Center with Intravitreal Brolucizumab Switch for Treatment of Exudative Neovascular Age-Related Macular Degeneration

Ophthalmology and Therapy
Introduction To analyze visual and anatomical outcomes in patients switched to brolucizumab and previously treated with other intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for exudative neovascular age-related macular ...
Federico Beretta, Ilaria Zucchiatti, Riccardo Sacconi, Federico Fantaguzzi, Stefano Lingardo, Francesco Bandello, Giuseppe Querques   +6 more
doaj   +1 more source